Article
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Neuro-oncology - 17 Dec 2019
Appay Romain, Dehais Caroline, Maurage Claude-Alain, Alentorn Agusti, Carpentier Catherine, Colin Carole, Ducray François, Escande Fabienne, Idbaih Ahmed, Kamoun Aurélie, Marie Yannick, Mokhtari Karima, Tabouret Emeline, Trabelsi Nesrine, Uro-Coste Emmanuelle, Delattre Jean-Yves, Figarella-Branger Dominique
Abstract excerpt
BACKGROUND: The 2016 World Health Organization (WHO) classification of central nervous system tumors stratifies isocitrate dehydrogenase (IDH)-mutant gliomas into 2 major groups depending on the presence or absence of 1p/19q codeletion. However, the grading system remains unchanged and it is now controversial whether it can be still applied to this updated molecular classification. METHODS: In a large cohort of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.